
Join Dr. Michael Levy, neuroimmunologist at Massachusetts General Hospital, for a concise yet comprehensive 45-minute educational session on Neuromyelitis Optica Spectrum Disorder (NMOSD). This antibody-mediated autoimmune condition primarily affects the optic nerve and spinal cord, potentially leading to permanent disability. Dr. Levy's presentation is divided into four informative modules, covering NMOSD pathogenesis, diagnosis criteria, laboratory testing, imaging, and common misdiagnoses. Additionally, he discusses the safety and efficacy of approved and off-label therapy options, offering valuable insights for tailoring treatment plans to suit the unique needs of NMOSD patients.
Course Credit:
0.75 AMA PRA Category 1 CreditsTM
Dates:
Opens: 2023-10-27
Closes: 2024-10-27
Target Audience:
National audience of neurologists and MS specialists, as well as nurse practitioners and physician associates who specialize in neurology.
This activity is supported by an educational grant from Genentech, a member of the Roche Group.
Accreditation

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Additional Content Planners
Jennifer Champagne, PharmD, BCPS (Medical Writer)No significant relationships to disclose.
Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.
Annenberg Center for Health Sciences
Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals have been mitigated.
-
Michael Levy, MD, PhD
Associate Professor
Department of Neurology
Massachusetts General Hospital and Harvard Medical School
Cambridge, Massachusetts
Presenting Faculty
Downloads
Learning Objectives
- Describe to a peer how AQP4-IgG testing should be applied for the diagnosis of neuromyelitis optica (NMO)
- Interpret AQP4-IgG test results when evaluating a patient who is exhibiting a neurologic syndrome consistent with NMO
- Summarize to a peer the evidence for the clinical application of approved and off-label treatments for NMO
Faculty Disclosures
Michael Levy, MD, PhD
Advisory Board: Alexion, Genentech, Horizon, Mitsubishi, Sanofi, UCB